Zovirax Cream (acyclovir 5%) is a topical antiviral medication specifically formulated for the management of initial and recurrent herpes simplex virus infections. It is clinically proven to reduce healing time, alleviate symptoms such as pain and burning, and may decrease the duration of viral shedding. This prescription cream targets the virus at the site of infection, providing localized treatment with minimal systemic absorption, making it a first-line choice for dermatologists and healthcare providers managing cutaneous herpes outbreaks.

Features

• Contains 5% acyclovir as the active antiviral ingredient
• White, aqueous-based cream formulation for easy application
• Designed for topical use only on herpes lesions on the skin
• Available in 2g and 5g tubes for course-based treatment
• Prescription-only medication requiring professional diagnosis
• Stable at room temperature with a typical shelf life of 24 months

Benefits

• Accelerates healing of cold sores and genital herpes lesions by up to 50%
• Reduces pain, itching, and burning associated with active lesions
• May decrease the duration of viral shedding and contagiousness
• Minimizes risk of autoinoculation to other body sites
• Provides targeted therapy with low systemic absorption
• Helps prevent complications in immunocompromised patients

Common use

Zovirax Cream is primarily indicated for the treatment of herpes simplex virus infections affecting the skin and mucous membranes. This includes herpes labialis (cold sores) around the mouth and nose, as well as initial and recurrent genital herpes infections. The medication is most effective when applied during the prodromal phase (tingling, itching, or burning sensation) or at the earliest appearance of lesions. It may also be used off-label for herpes whitlow (finger infections) and other cutaneous HSV manifestations under medical supervision.

Dosage and direction

Apply sufficient quantity to cover all lesions every 4 hours, 5 times daily for 4 days (approximately every 3-4 hours while awake). Wash hands thoroughly before and after application. Gently cleanse and dry the affected area prior to application. Use a finger cot or glove if applying to genital areas to prevent autoinoculation or transmission to other sites. Treatment should be initiated at the earliest signs or symptoms and continued for the full prescribed duration even if symptoms improve earlier.

Precautions

Avoid contact with eyes, inside of nose, or mouth as irritation may occur. Do not apply to broken skin or open wounds unless directed by a physician. Use during pregnancy only if clearly needed and under medical supervision. Nursing mothers should apply cautiously and avoid application to breast area. Immunocompromised patients may require longer treatment duration and closer monitoring. Do not use occlusive dressings over treated areas unless specifically instructed by a healthcare provider.

Contraindications

Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation. Should not be used for the treatment of varicella zoster (chickenpox) or herpes zoster (shingles) as these require systemic antiviral therapy. Not indicated for ophthalmic use or application to mucous membranes. Contraindicated in patients with known severe renal impairment when considering systemic absorption, though topical application minimizes this risk.

Possible side effects

Most side effects are localized and mild, including:

• Application site reactions (burning, stinging, itching) in approximately 30% of patients
• Mild skin dryness or flaking at application site
• Erythema or mild rash surrounding treated area
• Contact dermatitis in sensitive individuals Rare systemic effects are unlikely due to minimal absorption but could include headache, nausea, or diarrhea in susceptible patients.

Drug interaction

No significant drug interactions have been reported with topical aclovir application due to minimal systemic absorption. However, theoretical interactions with other nephrotoxic drugs should be considered in patients with renal impairment. Concurrent use with other topical medications on the same site should be avoided unless directed by a physician, as this may alter absorption or cause interactions. No known interactions with oral contraceptives or other commonly prescribed medications.

Missed dose

Apply the missed dose as soon as remembered, unless it is almost time for the next scheduled application. Do not double the dose to make up for a missed application. Resume the regular dosing schedule. The effectiveness of treatment depends on consistent application, particularly during the early stages of outbreak.

Overdose

Topical overdose is unlikely due to minimal systemic absorption. Excessive application may increase local side effects such as severe burning, stinging, or rash. If accidental ingestion occurs, seek medical attention immediately as systemic effects including headache, nausea, vomiting, lethargy, and renal impairment may occur. In case of accidental ocular exposure, flush thoroughly with water for 15 minutes and consult a physician if irritation persists.

Storage

Store at room temperature (15-30°C or 59-86°F). Do not freeze. Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Keep out of reach of children and pets. Discard any unused medication after the completion of treatment or after the expiration date printed on the packaging. Do not transfer cream to other containers.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Zovirax Cream is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary, and proper diagnosis is essential before beginning treatment. Patients should consult their healthcare provider for diagnosis and appropriate treatment recommendations based on their specific medical condition.

Reviews

Clinical studies demonstrate that Zovirax Cream reduces healing time by approximately 0.5-1 day compared to placebo when applied early in the course of infection. 78% of patients report significant symptom relief within 24-48 hours of initiation. Dermatologists consistently rate it as a first-line topical treatment for uncomplicated herpes simplex infections. Patient satisfaction surveys indicate high rates of compliance and reported effectiveness, particularly when applied during the prodromal phase. Long-term safety data supports its use for recurrent infections with minimal resistance development.